EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access

COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

Caio Max Sao Pedro Rocha Lima iD, Greg Yothers iD, Thomas J George iD, Howard S Hochster iD, Hanna K Sanoff iD, Deirdre J Cohen iD, Katherine A Guthrie iD, Samuel A Jacobs, Anwaar Saeed iD, Scott Kopetz iD, Linda H Colangelo, Tanner J Freeman und 10 weitere

Journal of Clinical Oncology · 2026

DOI: 10.1200/jco-25-03052 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Caio Max Sao Pedro Rocha Lima und 21 weiteren Autor:innen. Beteiligte Einrichtung: Atrium Health Wake Forest University Baptist Comprehensive Cancer Center, Winston-Salem, NC. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Immunotherapy for frontline mismatch repair–deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) is effective; however, nearly half of the patients treated with single-agent PD-1 therapy will progress within 12 months. Preclinical studies in CRC and clinical data from other cancers suggest that vascular endothelial growth factor inhibition and chemotherapy can synergize with PD-L1 inhibition. METHODS The NRG-GI004/SWOG-S1610 (COMMIT) three-arm prospective phase III open-label trial randomly assigned first-line dMMR/MSI-H mCRC patients (1:1:1) to either: mFOLFOX6 (oxaliplatin 85 mg/m², leucovorin 400 mg/m², 5-FU bolus 400 mg/m², and 46-hour infusional 5-FU 2,400 mg/m²)/bevacizumab (FFX/bev), or atezolizumab (atezo) monotherapy (840 mg IV once every 2 weeks), or the combination of FFX/bev/atezo. The primary end point was progression-free survival (PFS) in the intent-to-treat population. Because of KEYNOTE 177 results, the FFX/bev arm was closed after 20 patients were enrolled. The study continued with atezo alone versus FFX/bev/atezo, with a revised sample size of 100 patients in the two remaining arms (120 patients across all three arms). RESULTS From November 2017 to March 2025, a total of 102 patients were enrolled in the three arms: FFX/bev: n = 20, atezo: n = 41, and FFX/bev/atezo: n = 41. At a median follow-up of 46 months for the two arms (median age: 63.3 years; 47.6% female; 23.2% BRAF V600E mutated), PFS of FFX/bev/atezo was superior to that of atezo (hazard ratio [HR], 0.439 [95% CI, 0.23 to 0.84]; P = .0103) and below the critical value of 0.0152. The objective response rate was 86.1% versus 46%, and the disease control rate at 12 months was 64.7% versus 32.4% in the FFX/bev/atezo arm compared with the atezo-only arm, respectively. Grade 3 or higher adverse events of any attribution occurred in 52 patients (atezo: 18; combination arm: 34). CONCLUSION The combination of FFX/bev plus atezo led to significantly longer PFS compared with atezo monotherapy in the first-line treatment of dMMR/MSI-H mCRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabAntibodies, Monoclonal, HumanizedDNA Mismatch RepairHumansFemaleFluorouracilLeucovorinMiddle AgedOrganoplatinum CompoundsMaleAgedProspective StudiesAdultProgression-Free SurvivalMicrosatellite Instability

Substanzen

BevacizumabAntibodies, Monoclonal, HumanizedFluorouracilLeucovorinOrganoplatinum Compoundsatezolizumab

Autor:innen und Institutionen

  • Atrium Health Wake Forest University Baptist Comprehensive Cancer Center, Winston-Salem, NC.
  • NRG Oncology SDMC, Pittsburgh, PA.
  • Department of Biostatistics and Health Data Science, University of Pittsburgh, Pittsburgh, PA.
  • University of Florida Health Cancer Institute, Gainesville, FL.
  • NSABP Foundation, Inc, Pittsburgh, PA.
  • Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

ORCID-Profile: Caio Max Sao Pedro Rocha Lima, Greg Yothers, Thomas J George, Howard S Hochster, Hanna K Sanoff, Deirdre J Cohen, Katherine A Guthrie, Anwaar Saeed, Scott Kopetz, Dan S Zuckerman, Theodore S Hong, N Lynn Henry, Patricia A Ganz, Norman Wolmark, Michael J Overman

Förderung

  • NCI NIH HHS

Zitieren

APA

Rocha Lima, C. M. S. P., Yothers, G., George, T. J., Hochster, H. S., Sanoff, H. K., Cohen, D. J., Guthrie, K. A., Jacobs, S. A., Saeed, A., Kopetz, S., Colangelo, L. H., Freeman, T. J., Cole, S. W., Khalil, M., Devanna, S., Zuckerman, D. S., Hong, T. S., Henry, N. L., Ganz, P. A., …, & Overman, M. J. (2026). COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-03052

Vancouver

Rocha Lima CMSP, Yothers G, George TJ, Hochster HS, Sanoff HK, Cohen DJ, et al. COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer. Journal of Clinical Oncology. 2026. doi:10.1200/jco-25-03052

BibTeX
@article{RochaLima2026,
  author = {Rocha Lima, Caio Max Sao Pedro and Yothers, Greg and George, Thomas J and Hochster, Howard S and Sanoff, Hanna K and Cohen, Deirdre J and Guthrie, Katherine A and Jacobs, Samuel A and Saeed, Anwaar and Kopetz, Scott and Colangelo, Linda H and Freeman, Tanner J and Cole, Scott W and Khalil, Maged and Devanna, Swapna and Zuckerman, Dan S and Hong, Theodore S and Henry, N Lynn and Ganz, Patricia A and Blanke, Charles D and Wolmark, Norman and Overman, Michael J},
  title = {COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-25-03052}
}
Kostenlos starten →